Search Results - Selmaj, K.W.

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    Mi/INS;croRNA, a critical regulator of an autoimmune demyelination

    Mi/INS;croRNA, a critical regulator of an autoimmune demyelination by Mycko, M.P, Cichalewska, M, Mariasiewicz, M, Sliwinska, B, Cwiklinska, H, Selmaj, K.W

    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Adverse event profile of alemtuzumab over time in treatment-naïve patients with early, active relapsing–/INS;remitting multiple sclerosis (RRMS; CARE-MS I study)

    Adverse event profile of alemtuzumab over time in treatment-naïve patients with early, active relapsing–/INS;remitting multiple sclerosis (RRMS; CARE-MS I study) by Lycke, J, Arnold, D.L, Cohen, J.A, Coles, A.J, Confavreux, C, Fox, E.J, Hartung, H.-P, Havrdova, E, Selmaj, K.W, Weiner, H.L, Brinar, V, Giovannoni, G, Stojanovic, M, Lake, S.L, Margolin, D.H, Panzara, M, Compston, D.A.S

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Alemtuzumab improves visual outcomes in treatment-naïve patients with relapsing–/INS;remitting multiple sclerosis (RRMS): Analysis from the phase 3 CARE-MS I study

    Alemtuzumab improves visual outcomes in treatment-naïve patients with relapsing–/INS;remitting multiple sclerosis (RRMS): Analysis from the phase 3 CARE-MS I study by Balcer, L.J, Arnold, D.L, Cohen, J.A, Coles, A.J, Confavreux, C, Fox, E.J, Hartung, H.-P, Havrdova, E, Selmaj, K.W, Weiner, H.L, Brinar, V, Giovannoni, G, Stojanovic, M, Cinar, A, Margolin, D.H, Panzara, M, Compston, D.A.S

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: A CARE-MS substudy

    Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: A CARE-MS substudy by Margolin, D.H, Rizzo, M.A, Smith, G, Arnold, D.L, Cohen, J.A, Coles, A.J, Confavreux, C, Fox, E.J, Hartung, H.-P, Havrdova, E, Selmaj, K.W, Weiner, H.L, Brinar, V, Giovannoni, G, Miller, T.A, Stojanovic, M, Twyman, C.L, Lake, S.L, Panzara, M, Compston, D.A.S

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study

    Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study by Montalban, X, Inshasi, J.S, Coles, A.J, Hartung, H.P, Havrdova, E, Selmaj, K.W, Margolin, D.H, Palmer, J, Oyuela, P

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study

    Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study by Kieseier, B.C, Sahraian, M.A, Coles, A.J, Hartung, H.P, Havrdova, E, Selmaj, K.W, Margolin, D.H, Palmer, J, Oyuela, P

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  7. 7
    Circulating exosomes analysis reveals microRNA biomarkers of relapsing-remitting multiple sclerosis

    Circulating exosomes analysis reveals microRNA biomarkers of relapsing-remitting multiple sclerosis by Mycko, M., Selmaj, I., Cichalewska, M., Namiecinska, M., Galazka, G., Selmaj, K.W.

    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    P058 - Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study

    P058 - Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study by Montalban, X., Inshasi, J.S., Coles, A.J., Hartung, H.P., Havrdova, E., Selmaj, K.W., Margolin, D.H., Palmer, J., Oyuela, P.

    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    P045 - Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study

    P045 - Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study by Kieseier, B.C., Sahraian, M.A., Coles, A.J., Hartung, H.P., Havrdova, E., Selmaj, K.W., Margolin, D.H., Palmer, J., Oyuela, P.

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: